SAN
99.62
-0.56%↓
EI
248.8
-7.03%↓
SHL.DE
46.38
-7.09%↓
ARGX
535.8
+0.3%↑
FRE
39.76
+0.86%↑
SAN
99.62
-0.56%↓
EI
248.8
-7.03%↓
SHL.DE
46.38
-7.09%↓
ARGX
535.8
+0.3%↑
FRE
39.76
+0.86%↑
SAN
99.62
-0.56%↓
EI
248.8
-7.03%↓
SHL.DE
46.38
-7.09%↓
ARGX
535.8
+0.3%↑
FRE
39.76
+0.86%↑
SAN
99.62
-0.56%↓
EI
248.8
-7.03%↓
SHL.DE
46.38
-7.09%↓
ARGX
535.8
+0.3%↑
FRE
39.76
+0.86%↑
SAN
99.62
-0.56%↓
EI
248.8
-7.03%↓
SHL.DE
46.38
-7.09%↓
ARGX
535.8
+0.3%↑
FRE
39.76
+0.86%↑
24h
Corrente
Minimo
121.5
Massimo
126.6
Entrata | -142M 667M |
---|---|
Vendite | 152M 5.4B |
P/E Media del settore | 26.27 63.778 |
EPS | 2.2 |
Rendimento da dividendi | 1.34 |
Margine di Profitto | 12.311 |
EBITDA | 85M 1.6B |
Raccomandazioni | Fortemente da comprare |
---|---|
Previsioni per 12 mesi | +39.46% upside |
Rendimento da dividendi Media del settore | 1.34% 2.39% |
---|---|
Utili prossimi | 15 mag 2025 |
Capitalizzazione di Mercato | 33B 98B |
---|---|
Apertura precedente | 124.87 |
Chiusura precedente | 121.85 |
By Trading Central
Fiducia
Strong Bearish Evidence
N/A / 126.35 Supporto e resistenza
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
6 mar 2025, 06:27 UTC
Merck KGaA Forecasts Earnings, Sales Growth After In-Line Results
DJ
LeggI
11 feb 2025, 07:03 UTC
Germany's Merck in Talks to Buy SpringWorks Therapeutics
DJ
LeggI
10 feb 2025, 16:38 UTC
SpringWorks Therapeutics Shares Rise on Report it May be Acquired
DJ
LeggI
6 mar 2025, 11:18 UTC
Impact from U.S. Tariffs Is Manageable for Merck KGaA, CEO Says -- Market Talk
DJ
LeggI
6 mar 2025, 11:14 UTC
Merck KGaA's Outlook Signals Greater Transparency -- Market Talk
DJ
LeggI
6 mar 2025, 08:20 UTC
Merck KGaA's Earnings Guidance Seems Soft Amid Semiconductor Uncertainty -- Market Talk
DJ
LeggI
6 mar 2025, 06:00 UTC
Merck KGaA Expects 2025 Net Sales Between EUR21.5B and EUR22.9B
DJ
LeggI
6 mar 2025, 06:00 UTC
Merck KGaA 2024 Adj EPS EUR8.63
DJ
LeggI
6 mar 2025, 06:00 UTC
Merck KGaA Expects 2025 EBITDA Before One-Time Items Between EUR6.1B and EUR6.6B
DJ
LeggI
6 mar 2025, 06:00 UTC
Merck KGaA 2024 EBIT EUR3.645B
DJ
LeggI
6 mar 2025, 06:00 UTC
Merck KGaA 2024 After-Tax Profit EUR2.79B
DJ
LeggI
6 mar 2025, 06:00 UTC
Merck KGaA 2024 Ebitda Before One-Time Items EUR6.07B
DJ
LeggI
6 mar 2025, 06:00 UTC
Merck KGaA 2024 EBITDA EUR5.78B
DJ
LeggI
6 mar 2025, 06:00 UTC
Merck KGaA 2024 Sales EUR21.16B
DJ
LeggI
6 mar 2025, 06:00 UTC
Merck KGaA Keeps Dividend at EUR2.20
DJ
LeggI
6 mar 2025, 06:00 UTC
Analysts Saw Merck KGaA 2024 Sales at EUR21.14B
DJ
LeggI
6 mar 2025, 06:00 UTC
Analysts Saw Merck KGaA 2024 Ebitda Before One-Time Items at EUR6.08B
DJ
LeggI
11 feb 2025, 16:45 UTC
Merck's Potential Springworks Deal Unlikely to Move Needle on Earnings -- Market Talk
DJ
LeggI
11 feb 2025, 10:54 UTC
Germany's Merck Potential Buy of SpringWorks Therapeutics Puts Its Strategy Into Question -- Market Talk
DJ
LeggI
11 feb 2025, 10:52 UTC
German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk
DJ
LeggI
6 gen 2025, 13:08 UTC
Merck KGaA: Transaction closed on Dec. 23, 2024
DJ
LeggI
6 gen 2025, 13:07 UTC
Merck KGaA: Didn't Disclose Financial Details
DJ
LeggI
6 gen 2025, 13:06 UTC
Merck KGaA: HUB's Organoid Offering Complements Merck KGaA's Cell Culture Portfolio
DJ
LeggI
6 gen 2025, 13:04 UTC
Merck KaA Acquires HUB Organoids Holding B.V. to Expand Its Next-Generation Biology Portfolio
DJ
LeggI
17 dic 2024, 13:05 UTC
Merck: Deal Expected to Close By End Dec. 2024
DJ
LeggI
17 dic 2024, 13:04 UTC
Merck: Terms of Deal Undisclosed
DJ
LeggI
17 dic 2024, 13:04 UTC
Merck Signs Pact to Buy HUB Organoids
DJ
LeggI
17 dic 2024, 13:03 UTC
Merck: Acquisition Advances Next Gen Biology Portfolio
DJ
LeggI
17 dic 2024, 13:03 UTC
Merck to Buy HUB Organoids Holding
DJ
LeggI
14 nov 2024, 11:15 UTC
Merck KGaA's Sales Target Dragged by Muted China Outlook -- Market Talk
DJ
LeggI
Modifica del prezzo
By TipRanks
Previsioni per 12 mesi
Media 175.86 EUR 39.46%
Alto 190 EUR
Basso 160 EUR
Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Merck KGaA - Dist negli ultimi 3 mesi.
By TipRanks
Fortemente da comprare
9 ratings
7
Acquista
2
Mantieni
0
Vendi
Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Merck KGaA - Dist negli ultimi 3 mesi.
By Trading Central
A breve termine
Strong Bearish Evidence
All events are bearish.
A termine intermedio
Weak Bullish Evidence
Recent bullish events outweigh bearish events.
A lungo termine
Strong Bearish Evidence
All events are bearish.
Spese di vendita e di amministrazione
Spese operative
Utile prima delle imposte
Vendite
Costo delle vendite
Utile lordo sulle vendite
Interessi passivi sul debito
EBITDA
Utile operativo
$